Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Geltrude Mingrone, Melanie J. Davies, David A. D’Alessio, Judith Fradkin, Walter N. Kernan, Chantal Mathieu, Peter Rossing, Apostolos Tsapas, Deborah J. Wexler, John B. Buse

Risultato della ricerca: Contributo in rivistaArticolo in rivista

520 Citazioni (Scopus)

Abstract

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.
Lingua originaleEnglish
pagine (da-a)2461-2498
Numero di pagine38
RivistaDiabetologia
Volume61
DOI
Stato di pubblicazionePubblicato - 2018

Keywords

  • Cardiovascular disease
  • Chronic kidney disease
  • Costs
  • Glucose-lowering therapy
  • Guidelines
  • Heart failure
  • Hypoglycaemia
  • Patient-centred care
  • Type 2 diabetes mellitus
  • Weight management

Fingerprint Entra nei temi di ricerca di 'Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)'. Insieme formano una fingerprint unica.

Cita questo